Tissue sealant containing fibrinogen, thrombin and carboxymethyl cellulose or salt thereof
    2.
    发明授权
    Tissue sealant containing fibrinogen, thrombin and carboxymethyl cellulose or salt thereof 有权
    含有纤维蛋白原,凝血酶和羧甲基纤维素的组织密封剂或其盐

    公开(公告)号:US06200587B1

    公开(公告)日:2001-03-13

    申请号:US09312415

    申请日:1999-05-14

    IPC分类号: A61F200

    摘要: A tissue sealant comprising thrombin, fibrinogen, and carboxylmethyl cellulose or an alkali metal or alkali earth metal salt thereof is disclosed. The tissue sealant of the present invention promotes a hemostasis of an injury to a skin surface or a viscus, a healing of an injury, an endothelium formation of a blood vessel, an adhesive activity of animal cells, such as endothelial cells or fibroblasts in vitro, and an adhesion and agglutination of platelets.

    摘要翻译: 公开了包含凝血酶,纤维蛋白原和羧甲基纤维素或其碱金属或碱土金属盐的组织密封剂。 本发明的组织密封剂促进对皮肤表面或粘液的损伤止血,损伤的愈合,血管的内皮形成,体外的动物细胞如内皮细胞或成纤维细胞的粘附活性 ,以及血小板的粘附和凝集。

    Hemostatic agent
    4.
    发明授权
    Hemostatic agent 有权
    止血剂

    公开(公告)号:US06214808B1

    公开(公告)日:2001-04-10

    申请号:US09312416

    申请日:1999-05-14

    IPC分类号: A61K31715

    摘要: A hemostatic agent, an age for promoting cellular adhesion and an agent for curing an injury, each comprising an alkali or alkali earth metal salt of carboxylmethyl cellulose, and a pharmaceutically acceptable carrier are disclosed.

    摘要翻译: 公开了一种止血剂,促进细胞粘附的时代和用于治疗损伤的药剂,其各自包含羧甲基纤维素的碱金属或碱土金属盐和药学上可接受的载体。

    ADHESION-PREVENTING MATERIAL
    5.
    发明申请
    ADHESION-PREVENTING MATERIAL 审中-公开
    粘合防止材料

    公开(公告)号:US20130040911A1

    公开(公告)日:2013-02-14

    申请号:US13638156

    申请日:2010-12-09

    摘要: Provided are a novel carboxymethyl cellulose (CMC) structure and a method for producing the same. The CMC structure of the present invention is useful as a medical material and particularly as an adhesion-preventing material, and has good biocompatibility and bioabsorbability and controllable periods of functioning and dissolving, or has both effects for preventing adhesions and wound healing.The CMC structure of the present invention is substantially composed of carboxymethyl celluloses, comprising an acid carboxymethyl cellulose and an alkaline metal carboxymethyl cellulose in a mixed state. The method of production of the present invention comprises subjecting the alkaline metal (or acid) carboxymethyl cellulose structure to an acid (or alkali) treatment, wherein the acid (or alkali) treatment is terminated before the alkaline metal (or acid) carboxymethyl cellulose is fully converted to the acid (or alkaline metal) carboxymethyl cellulose.

    摘要翻译: 提供了一种新型羧甲基纤维素(CMC)结构及其制备方法。 本发明的CMC结构作为医疗用材料,特别是作为防粘连材料是有用的,具有良好的生物相容性和生物吸收性,可控制的功能和溶解时间,或具有防止粘连和伤口愈合的两种效果。 本发明的CMC结构基本上由羧甲基纤维素组成,其包含酸性羧甲基纤维素和混合状态的碱金属羧甲基纤维素。 本发明的生产方法包括使碱金属(或酸)羧甲基纤维素结构经受酸(或碱)处理,其中酸(或碱)处理在碱金属(或酸)羧甲基纤维素是 完全转化为酸(或碱金属)羧甲基纤维素。

    Anti-human plasmin-.alpha..sub.2 -plasmin inhibitor complex antibodies,
hybridomas, and immunological determination method
    6.
    发明授权
    Anti-human plasmin-.alpha..sub.2 -plasmin inhibitor complex antibodies, hybridomas, and immunological determination method 失效
    抗人纤溶酶-2纤溶酶抑制剂复合抗体,杂交瘤和免疫测定方法

    公开(公告)号:US5888749A

    公开(公告)日:1999-03-30

    申请号:US920544

    申请日:1992-09-21

    CPC分类号: C07K16/38 C07K16/40

    摘要: A first monoclonal antibody which specifically reacts with a human .alpha..sub.2 -plasmin inhibitor complex (PIC) and a human plasminogen; a second monoclonal antibody which reacts with PIC and also with a human .alpha..sub.2 -plasmin inhibitor; a third monoclonal antibody which reacts with PIC, but does not react with a human plasminogen and a human .alpha..sub.2 -plasmin inhibitor; hybridomas which secrete the first to third monoclonal antibodies, and an immunoassay using the first to third monoclonal antibodies.

    摘要翻译: PCT No.PCT / JP91 / 01736 Sec。 371日期:1992年9月21日 102(e)日期1992年9月21日PCT 1991年12月19日PCT PCT。 公开号WO92 / 11384 日期1992年7月9日是与人α2-纤溶酶抑制剂复合物(PIC)和人纤溶酶原特异性反应的第一单克隆抗体; 与PIC反应并且与人α2-纤溶酶抑制剂反应的第二单克隆抗体; 与PIC反应但不与人纤溶酶原和人α2-纤溶酶抑制剂反应的第三单克隆抗体; 分泌第一至第三单克隆抗体的杂交瘤和使用第一至第三单克隆抗体的免疫测定。

    Anti-human soluble fibrin antibody, hybridoma, and immunoassaying method
    7.
    发明授权
    Anti-human soluble fibrin antibody, hybridoma, and immunoassaying method 失效
    抗人可溶性纤维蛋白抗体,杂交瘤和免疫测定法

    公开(公告)号:US5821068A

    公开(公告)日:1998-10-13

    申请号:US448547

    申请日:1995-09-22

    摘要: A monoclonal antibody that reacts with a human soluble fibrin but not with a human fibrinogen; a hybridoma that secretes the above antibody; and a method of assaying a human soluble fibrin with the above antibody. It is possible to determine the amount of soluble fibrin in the plasma of a patient specifically, readily and rapidly by agglutination and EIA without being affected by plasma fibrinogen, plasmin-degradation product of fibrinogen, fibrin fragment, and plasmin-degradation product of stabilized fibrin even without pretreating the plasma sample.

    摘要翻译: PCT No.PCT / JP94 / 01844 Sec。 371日期1995年9月22日 102(e)1995年9月22日PCT PCT 1994年11月1日PCT公布。 公开号WO95 / 12617 日期1995年5月11日一种与人溶纤维蛋白反应而不与人纤维蛋白原反应的单克隆抗体; 分泌上述抗体的杂交瘤; 以及用上述抗体测定人可溶性纤维蛋白的方法。 可以通过凝集和EIA而不受血浆纤维蛋白原,纤维蛋白原的纤溶酶降解产物,纤维蛋白片段和稳定的纤维蛋白的纤溶酶降解产物的影响来确定患者血浆中可溶性纤维蛋白的量 即使不预处理血浆样品。